Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (980)	7/31/1998 2:01:00 AM
From: swedelo	Read Replies (1) \| Respond to of 1580

Mr Wong, IMHO many people are missing the boat on MRKs new drug maxalt. There are more than 25 million people in the U.S. alone that suffer to some extent from migrane headaches. I have heard market price for the drug will run between $12-$15 per pill. Anyone who has ever had a migrane, which I have, will tell you they will gladly pay this. I have seen nothing to indicate that any other company has anything to compete with it. I think it is a blockbuster being kept fairly quiet. Also, I've noted a sudden and very noticeable increase in tv advertiseing for Propecia, Oddly just after the earnings came out and the stock tanked. Lots of coincidences here. If people really do some digging (not you personally as its obvious your very good about your dd) I think they will find that Mercks pipeline is in much better shape than they are being given credit for. Swedelo